Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Mesenchymal Precursor Cells (MPCs)
Mesenchymal Precursor Cells · 3 trials · 3 indications
Outcomes include the following safety parameters: * Number of and percent of subject with adverse events and serious adverse events * Clinically significant values and shifts from baseline in vital signs, physical examinations and electrocardiograms * Clinical laboratory tests (hematology, chemistry and urinalysis, flow cytometry with Class I and Class II PRA % with specificity)
Outcomes include the measurement of the following safety parameters: * Adverse events and serious adverse events(including hypoglycemia) * Vital signs (BP, HR, RR, O2 saturation) * Physical examinations * Results of clinical laboratory tests (hematology, biochemistry, and urinalysis, flow cytometry Class I and Class II PRA % with specificity, antibovine and antimurine antibody analysis) * Pulmonary function test * Electrocardiograms * Chest X-ray * Fundus oculi examination
| Arm | Type | Description |
|---|---|---|
| A1 | ACTIVE_COMPARATOR | 15 subjects randomized to receive 25 M allogeneic MPCs by transendocardial injection and mapping. |
| A2 | SHAM_COMPARATOR | 5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures. |
| B1 | ACTIVE_COMPARATOR | 15 subjects randomized to receive 75 M allogeneic MPCs by transendocardial injection and mapping. |
| B2 | SHAM_COMPARATOR | 5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures. |
| C1 | ACTIVE_COMPARATOR | 15 subjects randomized to receive 150 M allogeneic MPCs by transendocardial injection and mapping. |
| C2 | SHAM_COMPARATOR | 5 subjects randomized to receive standard-of-care treatment with mock mapping and injection procedures. |
| Cohort 1 | EXPERIMENTAL | Mesenchymal Precursor Cells (MPCs) - Dose 1 or Placebo |
| Cohort 2 | EXPERIMENTAL | Mesenchymal Precursor Cells (MPCs) - Dose 2 or Placebo |
| Cohort 3 | EXPERIMENTAL | MPC dose 3 or Placebo |
| Name | Type | Description |
|---|---|---|
| Mesenchymal Precursor Cells (MPCs) | BIOLOGICAL | 25 M allogeneic MPCs by transendocardial injection and mapping. |
| standard-of-care treatment with mock mapping and injection procedures. | PROCEDURE | Mock |
Inclusion Criteria: 1. NYHA ≥ 2. 2. Age \>20 and \<80. 3. Cardiomyopathy of ischemic or idiopathic etiology. 4. Subject is not a candidate for either percutaneous intervention or cardiac surgery as determined by both an interventional cardiologist and a cardiac surgeon. 5. LVEF (Left ventricular ej...
Top 3 of 6 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | ALN-ANG3, Evinacumab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE2 | Atrasentan |
| ProKidney Corp. Class A | PROK | 2 | - | Rilparencel |
Mesenchymal Precursor Cells are being studied for diabetic nephropathy, heart failure, and type 2 diabetes. The clinical program includes a Phase 1 trial in diabetic nephropathy and type 2 diabetes, a Phase 1 trial in type 2 diabetes, and a Phase 2 trial in heart failure. All three trials have been completed.
Mesenchymal Precursor Cells are being developed by Mesoblast Limited, which trades under the ticker MESO. The company is the sponsor of the clinical program evaluating this cell-based therapy across metabolic and cardiovascular indications.
Mesenchymal Precursor Cells are in clinical development, with completed Phase 1 and Phase 2 trials. The program includes two Phase 1 studies and one Phase 2 study. No active trials are currently listed, and the asset has not been approved by the FDA.
Three completed trials have evaluated Mesenchymal Precursor Cells: NCT01843387 in diabetic nephropathy and type 2 diabetes, NCT01576328 in type 2 diabetes, and NCT00721045 in heart failure. The heart failure study used transendocardial delivery and was a Phase 2 dose-escalation trial.
Yes, Mesenchymal Precursor Cells are also known as MPCs. The abbreviation MPCs is used in trial titles and scientific literature to refer to the same allogeneic cell therapy developed by Mesoblast Limited.